News
COMPANY NEWS
Dr. Marwan Sabbagh Joins the Cognoptix Scientific Advisory Board
Cognoptix Announces Formation of a New Board of Directors
Cognoptix developing an Alzheimer’s disease test using the eye
Cognoptix to Present at Biotech Showcase™ 2020, San Francisco, CA
Dr. Marwan Sabbagh Joins the Cognoptix Scientific Advisory Board
Cognoptix announced that Marwan Noel Sabbagh, MD has joined Cognoptix’ Scientific Advisory Board. Dr. Sabbagh will play a pivotal role in helping guide the strategic direction of the company to support the continued efforts of achieving FDA approval for the Sapphire II system.
A pioneer in creating and developing a simple, innovative, non-invasive eye scanning test to aid in the early detection and diagnosis of Alzheimer’s Disease: Cognoptix
Various healthcare researchers and companies are trying to innovate new methods to diagnose Alzheimer’s, but Cognoptix stands out from the rest with its Sapphire II system, detecting Alzheimer’s disease through a simple scan of the lens of the eye.
Cognoptix Appoints New Chief Medical Officer, Dr. Carl Sadowsky, MD, and Chief Financial Officer, Mike Kaswan, MBA, to Management Team
Cognoptix announced that Carl H. Sadowsky, MD, will serve as the company’s new Chief Medical Officer (CMO), and Mike Kaswan, MBA, will be Cognoptix’s Chief Financial Officer (CFO).
Cognoptix Announces Formation of a New Board of Directors
As another milestone of its Series R restart, recapitalization, and revitalization, the company named a new Board of Directors under President and CEO Susanne Wilke, Ph.D.
Cognoptix Co-Founder Lee Goldstein, M.D., Ph.D. Joins Cognoptix Board of Directors and Scientific Advisory Board
Cognoptix announces its co-founder, Lee Goldstein, M.D., Ph.D. has joined Cognoptix’s Scientific Advisory Board, serving as Co-Chair, and the company’s Board of Directors.
Cognoptix Announces New Scientific Advisory Board with Alzheimer’s Research Leaders
Cognoptix announced the formation of its new Scientific Advisory Board (SAB) with appointment of five world-class scientists and clinical researchers in AD.
Cognoptix Investor Presentation
December 2021
“Cognoptix: Pioneering the Early Detection of Alzheimer’s Disease”
Cognoptix was recently profiled by MedTech Outlook as one of the Top 10 Non-Invasive Device Solution Providers for 2020.
“A pioneer in creating and developing a simple, innovative, non-invasive eye scanning test to aid in the early detection and diagnosis of Alzheimer’s Disease: Cognoptix”
Various healthcare researchers and companies are trying to innovate new methods to diagnose Alzheimer’s, but Cognoptix stands out from the rest with its Sapphire II system, detecting Alzheimer’s disease through a simple scan of the lens of the eye.
INDUSTRY NEWS
FDA grants historic approval to Alzheimer’s drug designed to slow cognitive decline
The Food and Drug Administration approved the first new treatment for Alzheimer’s disease in nearly two decades, a landmark decision that has been eagerly awaited by millions of Americans
FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy
For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients.
Lecanemab Safely, Quickly Lowers Amyloid Clumps in Trial
Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid — the protein that forms toxic clumps in Alzheimer’s — in people in early disease stages, according to one-year, preliminary data from a Phase 2 trial’s ongoing extension phase.
The Battle Over an Alzheimer’s Treatment
Biogen’s promising drug is caught in the FDA’s political and bureaucratic limbo.
Eli Lilly Offers More Positive Data on Its Alzheimer’s Drug
Eli Lilly is presenting data Saturday that bolsters its claims that its experimental Alzheimer’s antibody therapy slows down the disease in early-stage patients
The Other Pandemic: What to Do About the Coming Alzheimer’s Crisis
With the world in the midst of an aging boom, the number of people living with Alzheimer’s or some form of dementia is expected to triple by 2050 to 152 million—a bit more than the population of Russia today.
Eli Lilly adds $23B in market cap as investors rush on promise that this will be the amyloid Alzheimer’s drug that works
While the world awaits the FDA’s decision on Biogen’s controversial aducanumab pitch, a Big Pharma rival says they now have data to support their own amyloid-clearing Alzheimer’s drug.
Lilly Alzheimer’s Drug Helped Patients in Small Trial
An experimental Alzheimer’s drug from Eli Lilly & Co. helped patients in a small trial, the company said, renewing hopes that researchers are closing in on therapies that can fight the disease.
New Film “The Artist’s Wife” Tells the Story of a Family Navigating an Alzheimer’s Diagnosis
The name “Dolby” is synonymous with the power of sound thanks to American inventor Ray Dolby, who passed away in September 2013 from Alzheimer’s disease.
Super-Agers Show Resistance to Tau and Amyloid Accumulation
PET neuroimaging reveals super-agers and those whose cognitive skills are above the norm for an advanced age have an increased resistance to tau and amyloid proteins.